Illumina Posts 40-percent Gain in Q1 Revenues as Net Loss Declines | GenomeWeb

NEW YORK, April 27 (GenomeWeb News) - Illumina today reported a 40-percent gain in first-quarter revenues, as total receipts for the quarter ended April 3 climbed to $15.1 million from $10.8 million year over year.

R&D spending increased 13 percent to $5.9 million from $5.2 million in the first quarter of 2004.

Net loss for the quarter fell to $1.2 million, or $.03 per share, from $3.9 million, or $.12 per share, in the first quarter of 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.